Neuronetics (FRA:NRC) PensionAndRetirementBenefit : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics PensionAndRetirementBenefit?

Neuronetics's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was €0.00 Mil.

Neuronetics PensionAndRetirementBenefit Historical Data

The historical data trend for Neuronetics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics PensionAndRetirementBenefit Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PensionAndRetirementBenefit

Get a 7-Day Free Trial

Neuronetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
PensionAndRetirementBenefit	Get a 7-Day Free Trial															-	-	-	-	-

Neuronetics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Neuronetics (FRA:NRC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (FRA:NRC) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

STIM:USA NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.